Pyrazolo-pyrimidinone compounds for use in methods of inhibiting wee1 a kinase
Patent Information
- Authority / Receiving Office
- EP · EP
- Patent Type
- Applications
- Current Assignee / Owner
- ACRIVON THERAPEUTICS INC
- Filing Date
- 2024-06-07
- Publication Date
- 2026-04-15
AI Technical Summary
Current Wee1A kinase inhibitors have limitations in potency and selectivity, and there is a need for compounds that can effectively inhibit both Wee1A kinase and Myt1 kinase to maximize therapeutic potential, particularly in cancer treatment where cancer cells often rely on these kinases for survival.
Development of pyrazolo-pyrimidinone compounds that act as inhibitors of Wee1A kinase and Myt1 kinase, offering improved potency and selectivity, which can be administered to patients or biological samples to treat various cancers by preventing premature entry into mitosis and DNA replication.
The pyrazolo-pyrimidinone compounds effectively inhibit Wee1A kinase and Myt1 kinase, potentially leading to enhanced cancer treatment outcomes by inducing cell death in cancer cells with defective DNA damage response mechanisms, thereby addressing the limitations of existing inhibitors.
Smart Images
Figure US2024033065_12122024_PF_FP_ABST